| Literature DB >> 34372845 |
Steven Ronsmans1,2, Jolien De Ridder3, Eline Vandebroek1,4, Stephan Keirsbilck1,5, Benoit Nemery1,2, Peter H M Hoet2, Steven Vanderschueren6,7, Wim A Wuyts3,8, Jonas Yserbyt9,10.
Abstract
BACKGROUND: Sarcoidosis most commonly affects lungs and intrathoracic lymph nodes, but any other organ can be involved. In epidemiological studies, many occupational and environmental exposures have been linked to sarcoidosis but their relationship with the disease phenotype has barely been studied.Entities:
Keywords: Extrapulmonary sarcoidosis; Occupational and environmental exposures; Sarcoidosis phenotypes
Mesh:
Substances:
Year: 2021 PMID: 34372845 PMCID: PMC8351152 DOI: 10.1186/s12931-021-01818-5
Source DB: PubMed Journal: Respir Res ISSN: 1465-9921
Demographic and clinical data of the included sarcoidosis patients according to exposure category
| Overall (n = 238) | Exposure | |||||||
|---|---|---|---|---|---|---|---|---|
| Reactive chemical (n = 26) | Inorganic dust (n = 74) | Organic dust (n = 63) | Contact with livestock (n = 15) | Close human contact (n = 31) | Admin work only (n = 42) | Active smoker (n = 43) | ||
| Gender | ||||||||
| Women | 84 (35%) | 5 (19%)§ | 3 (4.1%)* | 22 (35%) | 6 (40%) | 25 (81%)* | 22 (52%)* | 9 (21%)* |
| Men | 154 (65%) | 21 (81%)§ | 71 (96%)* | 41 (65%) | 9 (60%) | 6 (19%)* | 20 (48%)* | 34 (79%)* |
| Age at diagnosis | 42 (35–50) | 37 (34–49) | 41 (35–48) | 39 (34–48)§ | 47 (38–52) | 44 (39–50) | 42 (36–46) | 38 (30–46)* |
| Never smoker | 148 (62%) | 14 (54%) | 40 (54%)§ | 43 (68%) | 14 (93%)* | 21 (68%) | 30 (71%) | 0 (0%) |
| Past smoker | 47 (20%) | 6 (23%) | 17 (23%) | 13 (21%) | 1 (6.7%) | 5 (16%) | 6 (14%) | 0 (0%) |
| Active smoker | 43 (18%) | 6 (23%) | 17 (23%) | 7 (11%)§ | 0 (0%)§ | 5 (16%) | 6 (14%) | 43 (100%) |
| Packyears (for past or active smokers) | 10 (5–20) | 7.5 (5–20) | 10 (5–20) | 12 (5–20) | 45 | 5 (5–14) | 10 (9–15) | 10 (6–20) |
| Enlarged hilar/mediastinal lymph nodes | 235 (99%) | 25 (96%) | 73 (99%) | 63 (100%) | 15 (100%) | 31 (100%) | 40 (95%)§ | 43 (100%) |
| (Micro)nodules | 183 (77%) | 21 (81%) | 55 (74%) | 51 (81%) | 10 (67%) | 22 (71%) | 35 (83%) | 36 (84%) |
| Fibrotic changes | 13 (5.5%) | 2 (7.7%) | 4 (5.4%) | 2 (3.2%) | 0 (0%) | 2 (6.5%) | 5 (12%)§ | 4 (9.3%) |
| Airway abnormalities | 44 (18%) | 7 (27%) | 20 (27%)* | 9 (14%) | 1 (6.7%) | 3 (9.7%) | 8 (19%) | 10 (23%) |
| FVC %pred | 94 (85–105) | 91 (77–102) | 94 (81–103) | 90 (78–98)* | 94 (91–103) | 99 (86–108) | 94 (90–108)§ | 94 (81–106) |
| FEV1%pred | 89 (76–102) | 84 (70–98) | 89 (75–104) | 82 (71–92)* | 92 (87–98) | 90 (77–102) | 94 (80–106) | 81 (70–99)§ |
| FEV1/FVC% | 78 (73–83) | 76 (62–82)§ | 77 (74–82) | 76 (70–80)* | 80 (77–82) | 81 (71–85) | 80 (76–83)§ | 78 (67–83) |
| TLC %pred | 92 (83–100) | 88 (80–99) | 89 (80–98)§ | 86 (80–98)§ | 91 (86–97) | 94 (89–102) | 96 (88–100)§ | 86 (80–101) |
| TLCO %pred | 80 (68–92) | 74 (64–93) | 81 (67–95) | 80 (68–88) | 84 (74–96) | 81 (68–87) | 79 (69–90) | 73 (62–89)* |
| % Lymphocytes | 17 (10–25) | 19 (14–25) | 15 (10–21) | 15 (10–23) | 13 (7–33) | 18 (11–32) | 15 (7–25) | 14 (7–21) |
| Not available | 125 (53%) | 13 (50%) | 34 (46%) | 27 (43%) | 9 (60%) | 20 (65%) | 24 (57%) | 21 (49%) |
| Treated within first year after diagnosis | 118 (50%) | 10 (38%) | 41 (55%) | 33 (52%) | 5 (33%) | 16 (52%) | 21 (50%) | 26 (60%) |
| Oral corticosteroids | 116 (49%) | 10 (38%) | 41 (55%) | 33 (52%) | 5 (33%) | 16 (52%) | 19 (45%) | 26 (60%)§ |
| Methotrexate | 46 (19%) | 5 (19%) | 17 (23%) | 14 (22%) | 0 (0%)§ | 5 (16%) | 7 (17%) | 16 (37%)* |
| Azathioprine | 47 (20%) | 6 (23%) | 17 (23%) | 15 (24%) | 1 (6.7%) | 5 (16%) | 10 (24%) | 14 (33%)* |
| Chloroquine | 27 (11%) | 4 (15%) | 12 (16%) | 8 (13%) | 0 (0%) | 3 (9.7%) | 4 (9.5%) | 10 (23%)* |
Statistics presented: median (25–75%), n (%); Statistical tests performed, comparing exposed to non-exposed: Wilcoxon rank sum test, Fisher’s exact test or Pearson’s Chi-squared test; * when p < 0.05, §p < 0.10
Organ involvements of the included sarcoidosis patients according to exposure category
| Overall (n = 238) | Exposure | |||||||
|---|---|---|---|---|---|---|---|---|
| Reactive chemicals (n = 26) | Inorganic dust (n = 74) | Organic dust (n = 63) | Contact with livestock (n = 15) | Close human contact (n = 31) | Admin work only (n = 42) | Active smoker (n = 43) | ||
| Pulmonary involvement only | 164 (69%) | 17 (65%) | 47 (75%) | 27 (64%) | 32 (74%) | |||
| Intrathoracic lymph node | 235 (99%) | 25 (96%) | 73 (99%) | 63 (100%) | 15 (100%) | 31 (100%) | 40 (95%)§ | 43 (100%) |
| Lung | 191 (80%) | 22 (85%) | 59 (80%) | 53 (84%) | 11 (73%) | 24 (77%) | 34 (81%) | 38 (88%) |
| Liver | 23 (9.7%) | 1 (3.8%) | 8 (13%) | 4 (9.5%) | 3 (7.0%) | |||
| Spleen | 37 (16%) | 3 (12%) | 7 (11%) | 9 (21%) | 4 (9.3%) | |||
| Cardiac | 17 (7.1%) | 3 (4.1%) | 2 (3.2%) | 2 (6.5%) | 4 (9.5%) | 3 (7.0%) | ||
| Eye | 29 (12%) | 2 (7.7%) | 7 (9.5%) | 4 (6.3%)§ | 0 (0%) | 6 (19%) | 5 (12%) | |
| Skin (excluding erythema nodosum) | 23 (9.7%) | 2 (7.7%) | 6 (8.1%) | 8 (13%) | 1 (6.7%) | 2 (6.5%) | 3 (7.1%) | 7 (16%) |
| Erythema nodosum | 30 (13%) | 5 (19%) | 11 (15%) | 9 (14%) | 0 (0%) | 3 (9.7%) | 5 (12%) | 4 (9.3%) |
| Neurologic | 9 (3.8%) | 1 (3.8%) | 2 (2.7%) | 1 (1.6%) | 0 (0%) | 2 (6.5%) | 1 (2.4%) | 2 (4.7%) |
| Parotid/salivary gland | 8 (3.4%) | 0 (0%) | 1 (1.4%) | 3 (4.8%) | 2 (13%)§ | 2 (6.5%) | 2 (4.8%) | 0 (0%) |
| Bone marrow | 9 (3.8%) | 0 (0%) | 2 (2.7%) | 3 (4.8%) | 1 (6.7%) | 3 (9.7%)§ | 1 (2.4%) | 3 (7.0%) |
| Löfgren syndrome | 30 (13%) | 3 (12%) | 9 (12%) | 6 (10%) | 1 (7%) | 3 (10%) | 6 (14%) | 3 (7%) |
Statistics presented: n (%); Statistical tests performed, comparing exposed to non-exposed: Fisher’s exact test or Pearson’s Chi-squared test; * when p < 0.05, §p < 0.10
Final multivariable logistic regression models for six organ involvements showing associations with occupational and environmental exposures in patients with sarcoidosis
| Exposure | Pulmonary only (n = 164) | Liver involvement (n = 23) | Splenic involvement (n = 37) | Cardiac involvement (n = 17) | Eye involvement (n = 29) | Skin granulomas (n = 23) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 95% CI | p | OR | 95% CI | p | OR | 95% CI | p | OR | 95% CI | p | OR | 95% CI | p | OR | 95% CI | p | ||
| Reactive chemicals (n = 26) | – | – | – | 5.08* | 1.28–19.2 | 0.016 | – | – | ||||||||||
| Inorganic dust (n = 74) | 2.11* | 1.11–4.17 | 0.026 | – | – | 0.21* | 0.04–0.76 | 0.029 | – | – | ||||||||
| Organic dust (n = 63) | 1.86 | 0.95–3.82 | 0.079 | – | – | 0.22 | 0.03–0.91 | 0.066 | – | – | ||||||||
| Contact with livestock (n = 15) | 0.23* | 0.07–0.71 | 0.012 | 3.68* | 0.91–12.7 | 0.047 | 4.94* | 1.46–16.1 | 0.008 | 9.86* | 1.95–49.0 | 0.004 | 0.00 | > 0.99 | – | |||
| Close human contact (n = 31) | – | 4.33* | 1.57–11.3 | 0.003 | 3.78* | 1.47–9.46 | 0.005 | – | – | – | ||||||||
| Administrative work only (n = 42) | – | – | 2.52* | 0.99–6.16 | 0.046 | – | – | – | ||||||||||
| Active smoker (n = 43) | – | – | – | – | 3.26* | 1.33–7.79 | 0.008 | 2.50 | 0.89–6.54 | 0.069 | ||||||||
For each organ involvement a separate multivariable logistic regression model was constructed. Odd ratios shown result from the best-fit multivariable logistic regression models, using Akaike information criterion (AIC) for model selection. OR = Odds Ratio for having been exposed (cases with a given organ involvement versus all other cases) while adjusting for other exposures and covariates retained in the final models (See “Materials and methods”). CI = Confidence Interval; p = p-value; *when statistically significant (p < 0.05)